SCHEMBL901899

SCHEMBL901899

Nc1cc(-c2cccc(N)n2)ccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.57
PDPK1 O15530 1/20 0.49
DYRK1A Q13627 7/20 0.45
MAPT P10636 1/20 0.44
IRAK4 Q9NWZ3 2/20 0.43
KCNH2 Q12809 1/20 0.43
KARS1 Q15046 1/20 0.42
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
GSK3B P49841 1/20 0.41
NOS3 P29474 2/20 0.41
NOS1 P29475 2/20 0.41
NOS2 P35228 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KHK P50053 1/20 0.40
AAK1 Q2M2I8 1/20 0.40
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21084241 0.84 TGFBR1 (0.53) DYRK1AMAPTIRAK4KCNH2KARS1
SCHEMBL901581 0.84 MAP4K4 (0.52) ASIC3PDPK1MAPTKDM4EMEN1
SCHEMBL1225542 0.80 MAP4K4 (0.56) ASIC3PDPK1NOS3NOS2KDM4E
SCHEMBL9103256 0.78 PI4KA (0.52) ASIC3DYRK1AMAPTMKNK1MKNK2
SCHEMBL29733297 0.78 PI4KA (0.52) ASIC3DYRK1AMAPTMKNK1MKNK2
SCHEMBL901898 0.78 ASIC3 (0.69) ASIC3PDPK1MAPTNOS3NOS1
SCHEMBL4402187 0.76 DYRK1A (0.63) PDPK1DYRK1AMAPTMKNK1MKNK2
SCHEMBL30935767 0.76 DYRK1A (0.63) PDPK1DYRK1AMAPTMKNK1MKNK2
SCHEMBL21469731 0.76 ASIC3 (0.60) ASIC3PDPK1DYRK1AMAPTNOS3
SCHEMBL31380411 0.76 KMO (0.49) PDPK1DYRK1AMAPTKCNH2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110234637-A Pyrazole amide compounds useful as IRAK inhibitors 里格尔药品股份有限公司 2019-09-13 CN disclosed
EP-2668162-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES Novartis AG (CH) 2013-12-04 EP disclosed
WO-2012101063-A1 N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101062-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 EP disclosed
EP-2459535-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS Novartis AG (CH) 2012-06-06 EP disclosed
EP-2441755-A1 Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors Almirall, S.A. (ES) 2012-04-18 EP disclosed
WO-2012041476-A1 PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS ALMIRALL, S.A. (ES) 2012-04-05 WO disclosed
WO-2011026911-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 WO disclosed
WO-2011012661-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2011-02-03 WO disclosed